Repligen Corporation engages in the development and commercialization of bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, scale down validation of chromatography processes, and ELISA test kits. The company also provides filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Period	TotalRevenue
2015-12-31	$83.54M
2016-12-31	$104.54M
2017-12-31	$141.24M
2018-12-31	$194.03M
2019-12-31	$270.25M
2020-12-31	$366.26M
2021-12-31	$670.53M
2022-12-31	$801.54M
2023-12-31	$632.36M
2024-12-31	$634.44M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RGEN	$115.29	+0.00%	0.65M
3
4
5

Repligen Corporation (RGEN) Revenue History

Revenue Data

Get Repligen Corporation Data in Excel

More RGEN Financial Data